Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials

医学 利拉鲁肽 艾塞那肽 内科学 胰高血糖素样肽1受体 2型糖尿病 肠促胰岛素 杜拉鲁肽 赛马鲁肽 胰高血糖素 糖尿病 利西塞纳泰德 胰高血糖素样肽-1 2型糖尿病 不利影响 内分泌学 胰岛素 低血糖 安慰剂 血糖性 二甲双胍 药理学 耐受性 随机对照试验 联合疗法 受体 兴奋剂
作者
Xiang Xue,Ren Z,A Zhang,Qian Yang,W Zhang,Liu F
出处
期刊:International Journal of Clinical Practice [Wiley]
卷期号:70 (8): 649-656 被引量:12
标识
DOI:10.1111/ijcp.12847
摘要

Background Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising results in the treatment of type 2 diabetes. Herein, we compared the efficacy and safety of once-weekly GLP-1RAs with exenatide and liraglutide separately. Methods We systematically surveyed the pertinent literature using various databases. The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included. Our main end-points were control of glycaemia, body weight, hypoglycaemia and gastrointestinal adverse events (AEs). Results Our analysis included eight trials involving 5531 patients. Exenatide-long-acting release (LAR), dulaglutide and taspoglutide were more effective than twice-daily exenatide in reducing glycosylated haemoglobin A1c (HbA1c) and fasting blood glucose (FBG) levels and achieving HbA1c targets (< 7.0% and ≤ 6.5%). Liraglutide was as effective as dulaglutide and more effective than exenatide-LAR and albiglutide in controlling glycaemia. With regard to the effectiveness in decreasing body weight, exenatide-LAR, dulaglutide and taspoglutide were similar to exenatide whereas exenatide-LAR, dulaglutide and albiglutide were inferior to liraglutide. Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence of hypoglycaemia and of gastrointestinal, serious, or other AEs. Conclusions Once-weekly GLP-1RAs were more effective in controlling glycaemia and equally effective in decreasing body weight than twice-daily exenatide but were inferior to liraglutide in controlling these two parameters (dulaglutide was similar with liraglutide in controlling glycaemia). Once-weekly GLP-1RAs, exenatide and liraglutide had a similar risk of causing AEs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
熏同学完成签到,获得积分10
1秒前
慕青应助科研通管家采纳,获得10
2秒前
CodeCraft应助科研通管家采纳,获得10
2秒前
深情安青应助科研通管家采纳,获得10
2秒前
完美世界应助科研通管家采纳,获得10
2秒前
共享精神应助科研通管家采纳,获得10
2秒前
Onetwothree完成签到 ,获得积分10
2秒前
熊熊发布了新的文献求助10
3秒前
港岛妹妹完成签到,获得积分10
6秒前
青辞198完成签到 ,获得积分10
8秒前
雍州小铁匠完成签到 ,获得积分10
10秒前
花花完成签到 ,获得积分10
12秒前
二师兄小刘完成签到,获得积分10
16秒前
阔达的铅笔完成签到,获得积分10
18秒前
Skywalker完成签到,获得积分10
18秒前
wanci应助金甲狮王采纳,获得10
22秒前
fancy完成签到 ,获得积分10
25秒前
31秒前
oMayii完成签到 ,获得积分10
34秒前
35秒前
37秒前
可爱多完成签到 ,获得积分10
37秒前
金甲狮王发布了新的文献求助10
38秒前
astral完成签到,获得积分10
42秒前
熊熊完成签到,获得积分10
43秒前
牟稀应助jinyu采纳,获得50
47秒前
李家新29完成签到,获得积分10
51秒前
理想三旬完成签到,获得积分10
51秒前
自由小妍完成签到 ,获得积分10
55秒前
虚拟的冰香完成签到,获得积分10
55秒前
Java完成签到,获得积分10
56秒前
酸奶泡泡完成签到 ,获得积分10
1分钟前
认真莆完成签到,获得积分10
1分钟前
Fuchen完成签到,获得积分10
1分钟前
小猪熊完成签到 ,获得积分10
1分钟前
bkagyin应助金甲狮王采纳,获得10
1分钟前
俊逸沛菡完成签到 ,获得积分10
1分钟前
xiaozhang完成签到 ,获得积分10
1分钟前
你爸完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Boris Pesce - Gli impiegati della Fiat dal 1955 al 1999 un percorso nella memoria 500
Chinese-English Translation Lexicon Version 3.0 500
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 460
Aspect and Predication: The Semantics of Argument Structure 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2396595
求助须知:如何正确求助?哪些是违规求助? 2098746
关于积分的说明 5289432
捐赠科研通 1826225
什么是DOI,文献DOI怎么找? 910523
版权声明 560007
科研通“疑难数据库(出版商)”最低求助积分说明 486633